A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

Phase 2CompletedNCT00703833

Merck Sharp & Dohme LLC51 enrolled

Overview

The study will look at the effectiveness of MK0777 in patients with Generalized Anxiety Disorder.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Generalized Anxiety Disorder

Interventions

MK0777DRUG

Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777

Placebo (unspecified)DRUG

matching placebo

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or Female * Current diagnosis of Generalized Anxiety Disorder * Age 18 - 70 Exclusion Criteria: * Women who are pregnant, or breast-feeding * Use of illicit drugs * History of drug or alcohol dependence

Outcomes

Primary Outcomes

Measure the reduction of anxiety

Time frame: after 4 weeks and at end of study

Secondary Outcomes

Safety and efficacy

Time frame: throughout study and at end of study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.